Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
about
A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanomaTrial WatchRegulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingAnticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12Cancer vaccinesSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaMyeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patientsTumor-induced myeloid dysfunction and its implications for cancer immunotherapyImmune checkpoint blockade and interferon-α in melanoma.Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice.Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.PD-1 Blockade Expands Intratumoral Memory T Cells.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsPhenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.Safety biomarkers in preclinical development: translational potential.Myeloid-derived suppressor cell heterogeneity in human cancers.Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.IFN-λ cancer immunotherapy: new kid on the block.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
P2860
Q21245488-42C4CFE2-C342-4357-99E1-545590EBCBBFQ24618653-30A1C442-29D2-4AE4-A47E-BE487CA3C01BQ26742012-5C33847D-1B55-4932-82E3-688EDDEBA509Q26796316-5B11A354-B6CF-4A4C-B1A7-F9DD7EDFBDB7Q27024438-9D8E5ADB-E534-448A-AB2B-0A6CED9C2110Q28067023-FEEF6C20-09BE-4185-8B93-7D20AA3ACE9FQ34250873-EE1D7108-9682-4653-9528-B7E59D833C53Q34810257-54E4A05F-2D6C-45C4-AF07-FC1CE6A545C7Q35598991-88317584-31A3-4B0D-B618-C140D8B96D11Q35608653-89BE9B9E-057C-44A9-8524-CCE7F0A56068Q35831375-3636FDBE-1905-4EE4-BB13-C3B0D2613412Q36061606-89B391B7-936B-49A7-9110-51672F204420Q36206582-E83D79B0-8C49-4E82-973F-44C193983A93Q36275124-7BEB0145-025C-4082-8710-B0C2F84B6C0CQ36283876-005A3976-43BF-43CB-89BB-65D85D7CFF4AQ36642804-DF86F7E9-B5A0-4A26-B59A-673A7C250AF4Q36711007-EA01750C-B8AA-48B1-9AB2-5FCF6F183EF7Q36869880-B400AA80-F824-49B2-868E-22F2EBEA2848Q37024260-9362F2CE-A805-4453-AAC7-8A1759B8EBCFQ37222132-8B8E8A2F-A8F9-427C-A6F4-CA2C618C4291Q37548776-A3E9C70D-72D6-478B-895D-CD57DA7EDCDFQ37626265-4504C5B9-C67A-49B0-9E56-F89A9A076D72Q37684031-F4F02D15-772A-40D9-B89D-7A926D2C1955Q38148980-BA0B2EF1-6FD0-4930-A8BD-7D38300EC5D7Q38223250-43CFA3BF-EA8D-49F9-BF20-467B9EF6F80FQ38271877-C69DEC44-E278-4F99-92AF-601FA2906923Q38534285-DAF0D37C-6326-4441-B1CC-BE738460D934Q38887297-3F6EC852-B965-4384-90D2-D6F2E6A2CE5DQ44017442-33FD2717-CA66-4427-9880-4F5C9F5FAE34Q50116255-B7C7DF0D-503A-433E-ABCA-9B88D182B3E5Q53491955-3BBA6BF9-C740-4A72-B5DE-4417C5631BC6Q55619003-999FC9D5-0645-4F5B-B63D-0EC7174A7CB6
P2860
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Differing patterns of circulat ...... -CSF with peptide vaccination.
@ast
Differing patterns of circulat ...... -CSF with peptide vaccination.
@en
type
label
Differing patterns of circulat ...... -CSF with peptide vaccination.
@ast
Differing patterns of circulat ...... -CSF with peptide vaccination.
@en
prefLabel
Differing patterns of circulat ...... -CSF with peptide vaccination.
@ast
Differing patterns of circulat ...... -CSF with peptide vaccination.
@en
P2093
P2860
P1476
Differing patterns of circulat ...... -CSF with peptide vaccination.
@en
P2093
Ahmad A Tarhini
John M Kirkwood
Lisa H Butterfield
Pawel Kalinski
William E Gooding
Yongli Shuai
P2860
P304
P356
10.1097/CJI.0B013E318272569B
P577
2012-11-01T00:00:00Z